Related Experiment Video
Updated: Jun 1, 2026
05:07
Multimodality Diagnosis of Mesenteric Ischemia
Published on: July 21, 2023
Potential for anatomic localization in colorectal cancer using the SCM test
1BAR ILAN UNIV,DEPT PHYS,JEROME SCHOTTENSTEIN CELLSCAN CTR EARLY DETECT CA,IL-52900 RAMAT GAN,ISRAEL. TEL AVIV UNIV,SACKLER FAC MED,TEL AVIV SOURASKY MED CTR,DEPT ONCOL,IL-69978 TEL AVIV,ISRAEL.
Oncology Reports
|May 20, 2011
Summary
The structuredness of the cytoplasmic matrix (SCM) test shows high accuracy for colorectal cancer detection. Prominent SCM test changes may indicate cecal cancers, a hard-to-reach area.
Area of Science:
- Oncology
- Medical Diagnostics
- Biophysics
Background:
- Colorectal cancer (CRC) diagnosis relies on sensitive and specific methods.
- The structuredness of the cytoplasmic matrix (SCM) test is a diagnostic tool for CRC.
- Early detection of cecal cancers is challenging due to anatomical location.
Purpose of the Study:
- To evaluate the diagnostic performance of the SCM test in 81 colorectal cancer cases.
- To investigate potential correlations between SCM test results and the anatomic location of colorectal cancer.
- To assess the SCM test's utility in identifying cancers in hard-to-reach locations like the cecum.
Main Methods:
- Analysis of 81 confirmed colorectal cancer cases.
- Application of the structuredness of the cytoplasmic matrix (SCM) test.
- Subgroup analysis based on the anatomic location of the malignancy.
- Evaluation of diagnostic sensitivity, specificity, and predictive values.
Main Results:
- The SCM test demonstrated high diagnostic sensitivity (92%) and specificity (92.6%).
- Positive and negative predictive values were 96.3% and 84.7%, respectively.
- A trend suggested more pronounced SCM test changes in cecal cancers compared to other locations.
Conclusions:
- The SCM test is a highly accurate method for diagnosing colorectal cancer.
- Findings suggest the SCM test may be particularly valuable for detecting cancers in the cecum.
- Further site-specific surveillance is recommended to validate the association between SCM test changes and cecal cancers.
